Anesiva Plans Staged Launch For Its Topical Anesthetic
This article was originally published in The Pink Sheet Daily
Following a possible late 2007 pediatric approval for lead compound 3268, Anesiva will gear up for entry into the adult topical local anesthetic market.
You may also be interested in...
Firm is initially seeking a pediatric indication for needle-free system but plans to expand label to include adults following completion of Phase III trial.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.